Genmab AS - Asset Resilience Ratio

Latest as of December 2025: 0.00%

Genmab AS (GMAB) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Genmab AS to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

$0.00

Cash + Short-term Investments

Total Assets

$12.84 Billion

All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2005–2025)

This chart shows how Genmab AS's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Genmab AS.

Liquid Assets Composition Over Time

This chart breaks down Genmab AS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Genmab AS long-term investment intensity to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$0.00	0%
Total Liquid Assets	$0.00	0.00%

Asset Resilience Insights

Limited Liquidity: Genmab AS maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company maintains a balanced mix of cash and short-term investments.

Genmab AS Industry Peers by Asset Resilience Ratio

Compare Genmab AS's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Aurinia Pharmaceuticals Inc NASDAQ:AUPH	Biotechnology	33.23%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%

Annual Asset Resilience Ratio for Genmab AS (2005–2025)

The table below shows the annual Asset Resilience Ratio data for Genmab AS.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	0.00%	$0.00	$12.84 Billion	--
2024-12-31	24.54%	$11.24 Billion	$45.81 Billion	-13.06pp
2023-12-31	37.60%	$13.27 Billion	$35.29 Billion	-3.67pp
2022-12-31	41.27%	$12.43 Billion	$30.12 Billion	-0.88pp
2021-12-31	42.15%	$10.38 Billion	$24.63 Billion	+0.44pp
2020-12-31	41.71%	$8.82 Billion	$21.14 Billion	-7.28pp
2019-12-31	48.99%	$7.42 Billion	$15.14 Billion	-16.88pp
2018-12-31	65.87%	$5.57 Billion	$8.46 Billion	+4.15pp
2017-12-31	61.72%	$4.08 Billion	$6.60 Billion	-7.29pp
2016-12-31	69.01%	$3.61 Billion	$5.24 Billion	+1.89pp
2015-12-31	67.12%	$2.62 Billion	$3.90 Billion	-13.17pp
2014-12-31	80.28%	$2.30 Billion	$2.87 Billion	+0.07pp
2013-12-31	80.21%	$1.39 Billion	$1.73 Billion	-4.66pp
2012-12-31	84.87%	$1.44 Billion	$1.69 Billion	+18.69pp
2011-12-31	66.19%	$1.04 Billion	$1.56 Billion	+3.79pp
2010-12-31	62.39%	$1.55 Billion	$2.48 Billion	+25.62pp
2009-12-31	36.77%	$816.91 Million	$2.22 Billion	-53.20pp
2007-12-31	89.97%	$3.56 Billion	$3.96 Billion	+18.20pp
2006-12-31	71.77%	$1.30 Billion	$1.80 Billion	+8.18pp
2005-12-31	63.60%	$871.56 Million	$1.37 Billion	--

pp = percentage points

About Genmab AS

NASDAQ:GMAB USA Biotechnology

Market Cap

$20.97 Billion

Market Cap Rank

#1539 Global

#605 in USA

Share Price

$34.15

Change (1 day)

+4.59%

52-Week Range

$23.85 - $35.34

All Time High

$48.72